Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Pronova Starts Dosing in Phase I Clinical Trial of PRC-4016

Sept. 19 (Bloomberg) -- Pronova BioPharma ASA started dosing in a Phase I clinical trial of PRC-4016, a new chemical entity for the treatment of combined dyslipidemia.

Link to Statement:{NSN LRRI293PWT1C <GO>}

Link to Company News:{PRON NO <Equity> CN <GO>}

To contact the editor responsible for this story: Meera Bhatia at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.